Microbiome – Targeted Therapeutics in Immunology – Thematic Research
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The microbiome is considered the genetic material of all microorganisms existing in and on the human body. Although the primary site of aggregated microbes is in the gastrointestinal (tract, populations of microorganisms are also found on the surface of the skin as well as in the upper and lower respiratory tract.
The microbiome-targeting therapeutics in immunology thematic research report will help you in developing and designing your in-licensing and out-licensing strategies, using a detailed overview of current deals and technologies to identify companies with the highest potential. This report will also help you to develop business strategies by understanding the trends shaping and driving the global microbiome-targeting therapy market.
Microbiome-Targeting Therapeutics in Immunology: Key Trends and Opportunities
The key trends that are associated with microbiome-targeting therapeutics in immunology theme can be classified into industry trends and regulatory trends. Some of the key industry trends impacting microbiome-targeting therapeutics in immunology include therapy approval, partnerships with big pharma, and others. Numerous partnerships and mergers and acquisitions (M&A are expected to occur in the future as the space continues to mature.
Even though there are currently low-priced generic products for mild to moderate patients, they are often not effective enough to provide complete relief. Mild to moderate patients are the focus of many microbiome-targeting drugs currently in development, including late-stage agents such as SER 287 B 244.
Microbiome-Targeting Therapeutics in Immunology: Value Chain
The key value chain components of microbiome-targeting therapeutics in the immunology theme are GI indications, dermatological indications, and respiratory indications.
Dermatological indications: The key layers of dermatological indications are Acne, AD, and PsO. There are 13 microbiome targeting drugs currently being developed for the treatment of GI diseases, the majority of which target UC Almost all of them are formulated for oral administration and work via targeted release of microbial strains to restore the intestinal microflora.
Microbiome-Targeting Therapeutics in Immunology Value Chain
To know more about microbiome-targeting therapeutics in the immunology value chain download a free report sample
Microbiome-Targeting Therapeutics in Immunology: Current Therapy
The only microbiome-targeting therapy currently available is fecal microbiota transplant, which is being explored in clinical trials for the treatment of GI indications such as IBD and IBS. Among ongoing trials of FMT in the US and 5EU, the majority are studying the use of the treatment in IBD, particularly UC.
Microbiome-Targeting Therapeutics in Immunology: Pipeline Products
The key products in the pipeline in microbiome-targeting therapeutics in immunology are Thetanix, Sibofimloc, RBX-2660, JNJ-72537634, BX003, and others. There are currently more than 20 microbiome-targeting therapeutics in development in the US and 5EU. Most are being developed by small to mid-size biotech companies specializing in the microbiome space.
Microbiome-Targeting Therapeutics in Immunology - Competitive Landscape
Some of the leading companies developing microbiome-targeting therapeutics in immunology are 4D Pharma, Enterome & Takeda, Seres Therapeutics, Rebiotix, Intralytix & Ferring International, Vedanta Biosciences, and others.
Microbiome-Targeting Therapeutics in Immunology Industry Overview
Report Pages | 110 |
Regions Covered | Global |
Key Trends | Industry Trends and Regulatory Trends |
Key Therapy | Fecal Microbiota Transplant |
Key Pipeline Products | Thetanix, Sibofimloc, RBX-2660, JNJ-72537634, BX003, and Others |
Leading Companies | 4D Pharma, Enterome & Takeda, Seres Therapeutics, Rebiotix, Intralytix & Ferring International, Vedanta Biosciences, and Others |
Scope
- Overview of microbiome therapies including classification of therapy and technologies, regulatory and market access details, and product & company profiles.
- Quotes from US- and 5EU-based key opinion leaders.
- Key topics covered for microbiome therapy in immunology in the US and 5EU include trends, value chains, market analysis, opportunities, challenges, unmet needs, and high-value deals.
- Pipeline analysis: Comprehensive data split across different phases and indications, emerging novel trends under development, and analysis of the most promising late-stage pipeline drugs for classes of microbiome therapies.
- Analysis of the key dynamics of the microbiome-targeting therapy market. Insightful review of the key industry drivers and challenges. Deals and R&D strategies covered to highlight business opportunities.
Key Highlights
- The main drivers of growth include increased development interest from large pharmaceutical companies and partnerships with small and mid-size biotechs.
- The main barriers to growth include market access issues such as the potential lack of reimbursement by payors for some indications and potential safety concerns, such as those seen in the use of fecal microbiota transplant (FMT).
- The most important unmet needs for microbiome therapies include the need for additional therapy options for mild-to-moderate patients, the lack of knowledge and clinical data regarding the mechanism of action, as well as current low utilization of microbiome therapies like FMT.
- The regulatory agencies of the US and 5EU are beginning to develop the definition of LBPs to describe microbiome-targeting therapies derived from live strains. However, a unique formal regulatory approval track has not yet been defined.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current deals and technologies to identify companies with the highest potential.
- Develop business strategies by understanding the trends shaping and driving the global microbiome-targeting therapy market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global microbiome-targeting therapy market in the future.
- Design your development strategy through a review of potential novel targets or combinations across indications.
- Understand the challenges and strategies impacting the development of microbiome-targeting therapy agents in preclinical studies and clinical trials.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the classes of microbiome-targeting therapy and indications that present maximum opportunities for consolidations, investments, and strategic partnerships.
Enterome Bioscience
Takeda Pharmaceuticals
Seres Therapeutics
Rebiotix
Intralytix
Ferring International
Vedanta Biosciences
BiomX
Johnson & Johnson
NuBiyota
KoBioLabs
Kaleido Biosciences
AOBiome
MatriSys Bioscience
Siolta Therapeutics
Forte Biosciences
Naked Biome
Evelo Biosciences
Table of Contents
Frequently asked questions
-
What key trends are shaping the microbiome-targeting therapeutics in immunology theme?
Some of the key trends impacting microbiome-targeting therapeutics in immunology theme include industry and regulatory trends.
-
What is the key therapy in microbiome-targeting therapeutics in the immunology theme?
Fecal microbiota transplant or FMT is the only therapy in microbiome-targeting therapeutics in the immunology theme.
-
Which are the key pipeline products in the microbiome-targeting therapeutics in the immunology theme?
The key products in the pipeline in microbiome-targeting therapeutics in immunology are Thetanix, Sibofimloc, RBX-2660, JNJ-72537634, BX003, and others.
-
Which companies are associated with the microbiome-targeting therapeutics in immunology theme?
Some of the leading companies developing microbiome-targeting therapeutics in immunology are 4D Pharma, Enterome & Takeda, Seres Therapeutics, Rebiotix, Intralytix & Ferring International, Vedanta Biosciences, and others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.